Literature DB >> 11343606

The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test-retest reliability and concurrent validity.

Anton J. M. Loonen, Cees H. Doorschot, Dianne A. van Hemert, Marc C. J. M. Oostelbos, Arnold E. S. Sijben.   

Abstract

The SADIMoD is a newly developed instrument, consisting of a compilation of rating scales, to measure the severity of drug-induced movement disorders: dystonia, dyskinesia, Parkinsonism, akathisia, ataxia, and several types of tremors. The test-retest reliability of this scale and the concurrent validity with the Abnormal Involuntary Movement Scale (AIMS), the Simpson-Angus Scale (SEE) and the Barnes Akathisia Scale (BAS) was assessed in 31 patients [20 male/11 female; 57.1+/-16.5 yr (mean+/-S.D.)] with a variety of movement disorders by six teams of investigators. The teams were trained by means of a standard package of instruction material to such an extent that a single member of the team could represent the entire team. Each patient was rated according to the AIMS, SEE and BAS and recorded on videotape according to the SADIMoD Schedule. These video-recordings were scored twice; first, in consensus by the entire team and secondly [110.3+/-58.0 d (mean+/-S.D.) later] by a single representative of that team. One team underwent a major change between scoring and was excluded from this analysis. Despite these difficult circumstances, these first and second ratings correlated to a highly significant degree with Spearman's correlation coefficients of 0.57 to 0.88 (median 0.69). The homogeneity of the applied scales was good (Cronbach's a = 0.75-0.94). Convergent validity was found between the SADIMoD dyskinesia and (to a lesser extent) dystonia scales and the AIMS as well as between the akathisia sub-scales and the BAS, with divergent validity with the other sub-scales. The SEE discriminated less well between the Parkinsonism sub-scale and the other sub-scales.

Entities:  

Year:  2000        PMID: 11343606     DOI: 10.1017/S1461145700002066

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  6 in total

1.  The Assessment and Treatment of Antipsychotic-Induced Akathisia.

Authors:  Tamara Pringsheim; David Gardner; Donald Addington; Davide Martino; Francesca Morgante; Lucia Ricciardi; Norman Poole; Gary Remington; Mark Edwards; Alan Carson; Thomas R E Barnes
Journal:  Can J Psychiatry       Date:  2018-04-23       Impact factor: 4.356

2.  Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population.

Authors:  Sven Janno; Matti M Holi; Katinka Tuisku; Kristian Wahlbeck
Journal:  BMC Neurol       Date:  2005-03-17       Impact factor: 2.474

3.  Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia.

Authors:  Ivan V Pozhidaev; Anastasiia S Boiko; Anton J M Loonen; Diana Z Paderina; Olga Yu Fedorenko; Gennadiy Tenin; Elena G Kornetova; Arkadiy V Semke; Nikolay A Bokhan; Bob Wilffert; Svetlana A Ivanova
Journal:  Appl Clin Genet       Date:  2020-04-22

4.  Neurobiological mechanisms associated with antipsychotic drug-induced dystonia.

Authors:  Anton Jm Loonen; Svetlana A Ivanova
Journal:  J Psychopharmacol       Date:  2020-09-09       Impact factor: 4.153

5.  Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia.

Authors:  Olga Yu Fedorenko; Diana Z Paderina; Elena G Kornetova; Evgeniya G Poltavskaya; Ivan V Pozhidaev; Anastasiia A Goncharova; Maxim B Freidin; Anna V Bocharova; Nikolay A Bokhan; Anton J M Loonen; Svetlana A Ivanova
Journal:  Diagnostics (Basel)       Date:  2022-06-22

6.  5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia.

Authors:  Ivan V Pozhidaev; Diana Z Paderina; Olga Yu Fedorenko; Elena G Kornetova; Arkadiy V Semke; Anton J M Loonen; Nikolay A Bokhan; Bob Wilffert; Svetlana A Ivanova
Journal:  Front Mol Neurosci       Date:  2020-04-24       Impact factor: 5.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.